mFOLFOX6 + bevacizumab combination therapy, once every two weeks

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (PARADIGM study)

An exploratory study of treatment sensitivity and prognostic factors in a efficacy and safety study of mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naive unresectable advanced or recurrent colorectal cancer